Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
June 24, 2026 | AI, HEOR, Market Access, RWE, evidence, evidence synthesis, genesis, literature reviews, slr
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers.
Developed in-house by Genesis scientists and refined through two years of real-world application in client evidence work, EVID AI provides a structured environment for conducting evidence synthesis activities, from rapid evidence queries and targeted literature reviews to ongoing literature surveillance and end-to-end systematic reviews.
Designed as a flexible working model, the EVID AI free access program enables teams and individuals to run projects independently, collaborate with Genesis experts, or delegate entirely, depending on their needs.
“Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
A single environment for evidence work
EVID AI brings evidence activities into one place, removing fragmentation across tools and processes, providing teams with a practical way to apply the same structured approaches used in evidence work within a single platform and workflow. It enables teams to:
- Identify and assess relevant literature
- Manage structured review workflows
- Monitor evolving evidence landscapes
- Support decision-making with clearer, more structured outputs
Designed for life sciences decision-making
EVID AI has been built and refined within Genesis’ own work, reflecting evidence synthesis needs across HEOR, RWE, Medical Affairs, and Market Access.
By aligning with real-world workflows, it supports faster, more informed decisions across the product lifecycle, supporting how therapies are evaluated, understood, and ultimately made available to patients.
Access and next steps
Approved users will receive free platform access through 31 December 2026, with optional access to Genesis expertise for protocol design, search strategy, screening, interpretation, and full project delivery.
Expert support remains separate from the platform offer and is provided based on user needs. Interested individuals can request access via the Genesis website.
Request free access at genesisrg.com.
About Genesis Research Group
EVIDENCE. EXPERIENCE. JUDGMENT.
Genesis Research Group is a global life sciences consulting firm specializing in evidence generation, health economics and outcomes research, real-world evidence, market access, pricing strategy, and stakeholder insights. Genesis combines rigorous evidence, deep expertise, and practical judgment to help companies reduce uncertainty and make better decisions across development, launch, access, and commercialization.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on...
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright's HEOR Theater presentation 'MFN Pricing: More Fun to Navigate – A European Roadmap to Success,' with potentially...
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice...
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice...
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...